NF-κB and EGFR participate in S1PR3-mediated human renal cell carcinomas progression

• Published in: Biochimica et biophysica acta. Molecular basis of disease Vol. 1868; no. 7; p. 166401
• Main Authors: Yan, Yali, Bao, Gegentuya, Pei, Jingyuan, Cao, Ying, Zhang, Chenyu, Zhao, Pengfei, Zhang, Yantao, Damirin, Alatangaole
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2022
• Subjects: Animals; Carcinoma, Renal Cell - genetics; EGFR; ErbB Receptors - genetics; Female; Humans; Kidney Neoplasms - genetics; Male; NF-kappa B; NF-κB; Proliferation; Renal cell carcinoma; S1PR3; Sphingosine-1-Phosphate Receptors; Tumor metastasis; OS; EGF; IHC; MLC; CCK; CDK; Proliferation; EMT; EGFR; TCGA; NF-κB; RCC; S1P; PTX; Renal cell carcinoma; GPCRs; S1PR3; Tumor metastasis
• DOI: 10.1016/j.bbadis.2022.166401
• ISSN: 0925-4439

The bioactive lipid sphingosine 1-phosphate (S1P) is implicated in many pivotal processes for the physiological and pathological actions via activating five types of G-protein-coupled S1P receptors (S1PR1‐5). The role of S1P in renal cell carcinoma (RCC) and its receptor subtype specific mediating mechanism are poorly studied. So we focus on the regulatory role of S1P in RCC progression and the receptor subtypes involved in S1P-induced actions, intending to further clarify a novel therapeutic target for RCC. Analysis of The Cancer Genome Atlas (TCGA) databases showed that the patients with high expression of S1PR3 had significantly worse overall than with low expression. We further demonstrated that S1P could promote proliferation, migration, and epithelial-mesenchymal transition (EMT) of renal cancer cells in vitro, and the actions were enhanced with the increase of S1PR3 expression. Meanwhile, the results in animal experiments also showed that S1PR3 could accelerate tumorigenesis and metastasis of RCC. Our study also clarified the mechanism for S1P induced cell proliferation is mediated by S1PR3/Gi/p38/Akt/p65/cyclin D1-CDK4 pathway and the main pathway for migration is S1PR3/Gi/q/ERK/p38/p65. In addition, S1PR3 was involved in epidermal growth factor (EGF)-induced actions by enhancing protein expression, not by transactivation of epidermal growth factor receptor (EGFR). These results also further supported our conclusion that the carcinogenic role of S1P/S1PR3 axis. Thus, our findings provide that S1PR3 may be a promising small molecular therapeutic target for S1PR3 expressed cancers. [Display omitted]